论文部分内容阅读
●苯氟雷司:撤市的建议欧洲药物处(EMEA)已建议将所有含苯氟雷司(benflurex)的药物在欧洲撤出市场。因为该药有引起心脏瓣膜病的风险,且风险大于其效益。该药是批准用于那些没有控制饮食的超体重糖尿病患者。EMEA人用医药产品委员会(CHMP)重温了该药的安全性及疗效后,赞同将该药撤市。CHMP并指出用该药后有引起心脏瓣膜病的风险,而该药治疗糖尿病的疗效是有限的。因此,CHMP得出的结论是:该药的风险大于效益,并建议将所有含有该药的产品从欧盟市
● Phenformin: Proposed Evacuations The European Medicines Agency (EMEA) has recommended that all benflurex-containing drugs be withdrawn from the market in Europe. Because the drug has the risk of causing heart valve disease, and the risk is greater than its benefits. The drug is approved for those over-weight diabetic patients who do not have a controlled diet. After reviewing the safety and efficacy of the drug, the EMEA Human Products Council (CHMP) agreed to withdraw the drug. CHMP and pointed out that the use of the drug has the risk of causing heart valve disease, and the efficacy of the drug in the treatment of diabetes is limited. As a result, CHMP concluded that the risk of the drug outweighs the benefits and recommends that all products containing the drug be imported from the European Union